Follicum has announced that the patent which previously received a Notice of Allowance from the US Patent and Trademark Office has now also been formally approved by the authority.
The patent is called “Peptides for Treatment of Diabetes” and the patent will be valid until 2038. The patent covers peptides from the company’s two peptide classes and their use in the treatment of diabetes and its complications. The patent will be formally approved on October 27, 2020.
“The US is by far the largest market for Follicum in diabetes and its complications. This formal patent approval is therefore of great importance to us and an important step in our global patent strategy. We are continuously working to expand our patent portfolio in our key markets,” says CEO of Follicum, Jan Alenfall.